NCT03254160 (SPIRIT) is a Phase 2 clinical trial of DNS-3379 in Ischemic Stroke, sponsored by Dart NeuroScience, LLC.

Who is sponsoring NCT03254160?

NCT03254160 is sponsored by Dart NeuroScience, LLC.

What drugs are being tested in NCT03254160?

Interventions in NCT03254160: DNS-3379, Placebo.

What condition does NCT03254160 study?

NCT03254160 studies Ischemic Stroke.

Is NCT03254160 still recruiting?

NCT03254160 is currently terminated. Last updated 1 February 2018.

Last reviewed 2018-02-01 · How we verify

NCT03254160: SPIRIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DNS-3379 vs. Placebo in Stroke Rehabilitation

Terminated Phase 2 Last updated 1 February 2018

What this trial tests

Phase 2 trial testing DNS-3379 in Ischemic Stroke in 1 participant. Terminated before completion.

Timeline

13 November 2017

Primary endpoint
31 December 2017

31 December 2017

Quick facts

Lead sponsor	Dart NeuroScience, LLC
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	1
Start date	13 November 2017
Primary completion	31 December 2017
Estimated completion	31 December 2017
Sites	16 locations across New Zealand, Australia

Drugs / interventions tested

DNS-3379 — full drug profile →
Placebo

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

Dart NeuroScience, LLC — full company profile →

Who can join

Adults 18 to 85, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blind, placebo-controlled parallel group outpatient 42-day treatment study that will utilize standard stroke rehabilitation outcome measures to evaluate the effect of DNS-3379 on upper extremity motor recovery in subjects following ischemic stroke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Dart NeuroScience, LLC trials

Trials by the same sponsor.

NCT03306329 — DNS-7801 vs. Placebo in Parkinson's Disease · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03254160 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dart NeuroScience, LLC
Last refreshed: 1 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03254160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing